Study of Lenacapavir for HIV Prevention
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to understand and sign a consent form.
- You must be willing to follow the study rules.
- You need to be at a study site and want or need PrEP for HIV prevention.
- You can be new to PrEP or have used oral or injectable PrEP before.
- You must be eligible for LEN PrEP according to standard care, including testing negative for HIV.
- You will receive counseling and then choose LEN PrEP, another method, or no PrEP.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This study follows people who are stopping long-acting injectable PrEP (cabotegravir or lenacapavir). It checks how long the drug stays in your body and helps make sure you stay protected during that time. You'll do monthly video visits, mail in blood samples, and fill out short surveys.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study offers a new injectable medication called lenacapavir to prevent HIV. It is for people who are HIV-negative and sexually active, and want to try a long-acting injection instead of daily pills.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.